search
Back to results

Protein Sorbent Properties of Montmorillonite in Vitro and in Vivo Models

Primary Purpose

Urea Cycle Disorders, Inborn, Other Metabolic Diseases

Status
Completed
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
montmorillonite 5 g
montmorillonite 3 g
Montmorillonite 1 g
Sponsored by
Luca Ronfani
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Urea Cycle Disorders, Inborn focused on measuring Montmorillonite, proteic diet, in vitro and in vivo models

Eligibility Criteria

25 Years - 30 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • healthy volunteers (12M, 13 F, 25-30 years). Fasting from morning

Exclusion Criteria:

  • not defined

Sites / Locations

  • Institute for Maternal and Child Health IRCCS Burlo Garofolo

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

No Intervention

Arm Label

montmorillonite 5 g

Montmorillonite 3 g

Montmorillonite 1 g

Control

Arm Description

5g Montmorillonite + 15 g protein (ratio 1:3)

3g Montmorillonite + 15 g protein (ratio 1:5)

1g Montmorillonite + 15 g protein (ratio 1:15)

A control goup will intake 15 g of protein alone

Outcomes

Primary Outcome Measures

Protein uptake evaluated with the blood MONT-protein ratio
A solution of MONT and whey protein dissolved in 200 ml of water at the three different ratios will be administered. The control group will intake 15g of protein alone. Blood samples will be centrifuged and analyzed by mass spectrometry (egilent HP5973 mass spectrometry).

Secondary Outcome Measures

Protein absorption by MONT in vitro
MONT and protein (whey protein) at three different ratio w/w (1:3, 1:5, 1:15) will be dissolved in acetate buffer 0.1M pH5 as well as a sample without MONT. Samples will incubate at RT for 1, 10, 30, 60 minutes and then centrifugate at 13000g. The surnatant will be analyzed by LOWRY method. Protein concentration will be expressed in mg/ml. The MONT ability of immobilization will be calculated respect to the protein control sample

Full Information

First Posted
October 21, 2013
Last Updated
March 8, 2017
Sponsor
Luca Ronfani
Collaborators
University of Trieste
search

1. Study Identification

Unique Protocol Identification Number
NCT02124330
Brief Title
Protein Sorbent Properties of Montmorillonite in Vitro and in Vivo Models
Official Title
Protein Sorbent Properties of Montmorillonite in Vitro and in Vivo Models
Study Type
Interventional

2. Study Status

Record Verification Date
March 2017
Overall Recruitment Status
Completed
Study Start Date
June 2013 (Actual)
Primary Completion Date
April 2015 (Actual)
Study Completion Date
April 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Luca Ronfani
Collaborators
University of Trieste

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Montmorillonite (MONT) is a phyllosilicate layered mineral with unique physicochemical properties, such as swelling and cation exchange capability. The aim of this project is to study, in healthy volunteers, the in vivo ability of MONT to reduce protein intestinal uptake. Furthermore, the study analyzed in vitro the MONT ability of immobilizing proteins.
Detailed Description
Montmorillonite (MONT) is a phyllosilicate layered mineral; chemically it is hydrated sodium calcium aluminium magnesium silicate hydroxide. Potassium, iron, and other cations are common substitutes and the exact ratio of cations varies with source. Due to its unique physicochemical properties, such as swelling and cation exchange capability, as well its mechanical and thermal stability, MONT can be efficiently used as matrix for immobilization of proteins with high molecular weight (e.g. Albumin) and proteins with low molecular weight (e.g.Aflatoxines). Therefore, MONT is used for therapeutic purposes, in pharmaceutical formulations and in food preparations. In vitro assays made in our laboratory, showed that MONT absorbs, in stable manner, alimentary proteins: beta-lactoglobulins, alfa lactoalbumines and the ratio MONT-protein (w/w) 1:3, 1:5, 1:15, results in the protein capture of 50, 27, 0 % of proteins respectively. The aim of this project is to study, in healthy volunteers, the in vivo ability of MONT to reduce protein intestinal uptake evaluated with the blood MONT- protein ratio. Furthermore, the study analyzed in vitro the MONT ability of immobilizing proteins at different ratio (w/w) 1:3, 1:5, 1:15.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Urea Cycle Disorders, Inborn, Other Metabolic Diseases
Keywords
Montmorillonite, proteic diet, in vitro and in vivo models

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
35 (Actual)

8. Arms, Groups, and Interventions

Arm Title
montmorillonite 5 g
Arm Type
Experimental
Arm Description
5g Montmorillonite + 15 g protein (ratio 1:3)
Arm Title
Montmorillonite 3 g
Arm Type
Experimental
Arm Description
3g Montmorillonite + 15 g protein (ratio 1:5)
Arm Title
Montmorillonite 1 g
Arm Type
Experimental
Arm Description
1g Montmorillonite + 15 g protein (ratio 1:15)
Arm Title
Control
Arm Type
No Intervention
Arm Description
A control goup will intake 15 g of protein alone
Intervention Type
Dietary Supplement
Intervention Name(s)
montmorillonite 5 g
Intervention Description
5g montmorillonite + 15 g protein (ratio 1:3)
Intervention Type
Dietary Supplement
Intervention Name(s)
montmorillonite 3 g
Intervention Description
3g MONT+ 15 g protein (ratio 1:5)
Intervention Type
Dietary Supplement
Intervention Name(s)
Montmorillonite 1 g
Intervention Description
1g MONT+ 15 g protein (ratio 1:15)
Primary Outcome Measure Information:
Title
Protein uptake evaluated with the blood MONT-protein ratio
Description
A solution of MONT and whey protein dissolved in 200 ml of water at the three different ratios will be administered. The control group will intake 15g of protein alone. Blood samples will be centrifuged and analyzed by mass spectrometry (egilent HP5973 mass spectrometry).
Time Frame
before administration and 30, 60, 90, 120 ,180 minutes after
Secondary Outcome Measure Information:
Title
Protein absorption by MONT in vitro
Description
MONT and protein (whey protein) at three different ratio w/w (1:3, 1:5, 1:15) will be dissolved in acetate buffer 0.1M pH5 as well as a sample without MONT. Samples will incubate at RT for 1, 10, 30, 60 minutes and then centrifugate at 13000g. The surnatant will be analyzed by LOWRY method. Protein concentration will be expressed in mg/ml. The MONT ability of immobilization will be calculated respect to the protein control sample
Time Frame
at time of the trial

10. Eligibility

Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
30 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: healthy volunteers (12M, 13 F, 25-30 years). Fasting from morning Exclusion Criteria: not defined
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tarcisio Not, MD
Organizational Affiliation
Institute for Maternal and Child Health IRCCS Burlo Garofolo
Official's Role
Principal Investigator
Facility Information:
Facility Name
Institute for Maternal and Child Health IRCCS Burlo Garofolo
City
Trieste
State/Province
Friuli Venezia Giulia
ZIP/Postal Code
34137
Country
Italy

12. IPD Sharing Statement

Learn more about this trial

Protein Sorbent Properties of Montmorillonite in Vitro and in Vivo Models

We'll reach out to this number within 24 hrs